On October 17, 2022, Aurinia Pharmaceuticals Inc. and Robert Huizinga, PhD RN, CNeph(C), its Executive Vice President, Research and Neil Solomons, M.D., its Chief Medical Officer, mutually agreed that Dr. Huizinga and Dr. Solomons would cease their employment with Aurinia, each effective October 31, 2022.
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
5.65 USD | +5.81% | +6.60% | -37.15% |
Jun. 14 | Transcript : Aurinia Pharmaceuticals Inc. - Shareholder/Analyst Call | |
Jun. 07 | ILJIN SNT Co Provides Information to Shareholders of Aurinia Pharmaceuticals | CI |
EPS Revisions
1st Jan change | Capi. | |
---|---|---|
-37.15% | 806M | |
+18.15% | 124B | |
+18.02% | 112B | |
+4.66% | 22.94B | |
-12.75% | 22.22B | |
-9.86% | 17.02B | |
-15.29% | 16.88B | |
-39.94% | 16.87B | |
+2.80% | 13.63B | |
+27.39% | 11.61B |
- Stock Market
- Equities
- AUPH Stock
- News Aurinia Pharmaceuticals Inc.
- Aurinia Pharmaceuticals Inc. Announces Management Departures